Current hematological, cytogenetic, and molecular responses of surviving patients by therapy
| . | Imatinib . | Allo-HSCT . | P . |
|---|---|---|---|
| No. of surviving patients | 39 | 38 | |
| Median follow-up (range), mo | 47 (25-108) | 65 (18-108) | .658 |
| CHR, no. (%) | 36 (92.3) | 38 (100) | .240 |
| MCR, no. (%) | 33 (84.6) | 38 (100) | .025 |
| CCR, no. (%) | 33 (84.6) | 38 (100) | .025 |
| MMR, no. (%) | 29 (74.4) | 38 (100) | .001 |
| CMR, no. (%) | 16 (41.0) | 37 (97.4) | .000 |
| . | Imatinib . | Allo-HSCT . | P . |
|---|---|---|---|
| No. of surviving patients | 39 | 38 | |
| Median follow-up (range), mo | 47 (25-108) | 65 (18-108) | .658 |
| CHR, no. (%) | 36 (92.3) | 38 (100) | .240 |
| MCR, no. (%) | 33 (84.6) | 38 (100) | .025 |
| CCR, no. (%) | 33 (84.6) | 38 (100) | .025 |
| MMR, no. (%) | 29 (74.4) | 38 (100) | .001 |
| CMR, no. (%) | 16 (41.0) | 37 (97.4) | .000 |